ASCRS•ASOA SYMPOSIUM & CONGRESS, SAN DIEGO 2015
Glaucoma Day: New treatment
possibilities on the horizon for glaucoma
by Vanessa Caceres and Rich Daly EyeWorld Contributing Writers
EyeWorld Daily News • The official ASCRS•ASOA Show Daily
Saturday, April 18, 2015
digital.eyeworld.org
continued on page 3
Drs. Sourdille and Ventura are
Honored Guests at this year's meeting
Even small leaks can lead to
BIG COMPLICATIONS.
Visit us in Booth #443
www.resuresealant.com
ReSure Sealant is indicated for intraoperative management of clear corneal incisions (up to 3.5mm) with a
demonstrated wound leak for which a temporary dry surface can be achieved, in order to prevent postoperative
fluid egress from such incisions following cataract surgery with intraocular lens (IOL) placement in adults.
P
hilippe Sourdille, MD,
and Marcelo Ventura,
MD, PhD, are Honored
Guests of ASCRS and
ALACCSA-R (LASCRS) at
the 2015 ASCRS•ASOA Symposium
& Congress. At today's ASCRS
Opening General Session, they will
be honored for their contributions
to ophthalmology.
Dr. Sourdille is an ophthalmic
legacy, with both his father and
grandfather being French ophthal-
mologists. He designed and patent-
ed several IOL models but has main-
tained a focus on posterior capsule
opacification and the treatment of
postoperative inflammation.
O
phthalmologists will soon
benefit from new classes
of glaucoma medications,
new surgeries, and new
drug delivery devices,
said John R. Samples, MD, Olym-
pia, Wash., at yesterday's ASCRS
Glaucoma Day.
While current glaucoma medi-
cations aim to lower IOP, there are
drugs on the horizon that will take
different approaches. These include
measuring the loss of retinal
ganglion cells and treating underly-
ing molecular abnormalities, Dr.
Samples said. Although there are
Dr. Sourdille is currently a
consultant in Europe, successively
working with Cornéal Laboratoires,
Croma Pharma, Cristalens, Medi-
contur, and Aptissen. Until 2002,
he practiced at a leading French
ophthalmology center that was
founded by his grandfather,
Clinique Sourdille.
Dr. Sourdille has had a career
filled with many milestones. In
1991, as president of the French
Implant Society (SAFIR), Dr.
Sourdille organized a club that
would later become the European
Society of Cataract & Refractive Sur-
geons (ESCRS). Along with Stephen
continued on page 3
Philippe Sourdille, MD Marcelo Ventura, MD, PhD
various drugs under investigation,
the one that is furthest along is
Rhopressa (Aerie Pharmaceuticals,
Bedminster, N.J.), a ROCK/NET
inhibitor that is currently in phase
3 trials, Dr. Samples said. Some of
the slated new drugs are part of drug
classes not previously used within
glaucoma.
There are also evolutions for
drug delivery devices within glauco-
ma, such as punctal plugs, contact
lens-style reservoirs, and reservoir
insertions, Dr. Samples added. These
updated delivery devices can help
Glaucoma Day speakers discussed topics including new treatment options, imaging,
and MIGS.
